Galaxy Biomedical Investment Co., Ltd. reported earnings results for the half year ended June 30, 2022. For the half year, the company reported sales was CNY 716.08 million compared to CNY 465.14 million a year ago. Revenue was CNY 779.78 million compared to CNY 492.02 million a year ago.

Net loss was CNY 6.01 million compared to CNY 187.95 million a year ago. Basic loss per share from continuing operations was CNY 0.0055 compared to CNY 0.1709 a year ago. Diluted loss per share from continuing operations was CNY 0.0055 compared to CNY 0.1709 a year ago.